

1 **Antibiotic Resistance related Mortality, Length of Hospital Stay, and Disability-Adjusted Life**
2 **Years at select Tertiary Hospitals in Uganda: *A retrospective study***

3 **Authors:** Jonathan Mayito¹, Flavia Dhikusooka¹, Daniel Kibombo¹, Andrew Busuge¹, Alex Andema²,
4 Alfred Yayi², Stephen Obbo², Richard Walwema¹, Francis Kakooza¹

5 1. Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala P.O. Box
6 22418, Uganda

7 2. Arua, Jinja, Mbale Regional Referral Hospitals, Ministry of Health, Kampala P.O. Box 7272,
8 Uganda

9

10 **Abstract**

11 **Background**

12 Antimicrobial Resistance (AMR) is a major global health threat but its burden has not been extensively
13 described in Uganda. We aimed to investigate the antibiotic resistance related mortality, length of
14 hospital stays (LOS) and Disability Adjusted Life Years (DALYs).

15 **Methods**

16 This was a retrospective study of clinical records of patients with infectious syndromes admitted at
17 Arua, Jinja and Mbale regional referral hospitals between October 2022 and September 2023. Data was
18 abstracted from clinical records and analyzed to derive the mortality, LOS, DALYs, and factors
19 associated with AMR and mortality using the modified Poisson regression model.

20 **Results:**

21 Of the 291 participants included in the analysis, 56.6% were males, 10% were living with HIV, and
22 their median age was 35 years (IQR: 21-56). The most common infectious syndromes were sepsis
23 (43.6%) and diarrhea (9.6%). The prevalence of antibiotic-resistant infections (ARI) was 29.6%, while
24 that for multi-drug resistant infections (MDRI) was 17.9%. Patients at Jinja and Mbale RRHs exhibited
25 a 2.42 and 2.05 higher risk of ARI respectively compared to those at Arua RRI. Overall, mortality due

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

26 to an infectious syndrome was 44.7%, of which 34.9% was due to ARI while 30.8% of the ARI related
27 mortality was due to MDR infections. Most deaths were due to sepsis (42.3%), followed by pneumonia
28 (15.4%) and meningitis (6.2%). Participants with comorbidities had higher risk of mortality due to ARI
29 (45% vs. 31% for those without comorbidities). Among Gram-negative bacteria, *Escherichia coli* and
30 *Klebsiella* spp contributed most to mortality, while among Gram-positives, *Staphylococcus aureus* and
31 *Enterobacter* spp contributed equally. Patients with ARI's LOS was 1.2 times higher than that for those
32 without ARI while a longer LOS was associated with a 21% higher ARI risk but a 24% decline in risk
33 of death. ARI was associated with higher DALYs, 235.4, compared to 147.0 for non-ARI.

34 **Conclusion**

35 The study revealed a high burden of AMR in Uganda, including a high prevalence of MDR and
36 associated mortality, particularly among patients with comorbidities. This indicates an urgent need for
37 stewardship and infection prevention strategies to control the AMR burden.

38 **Key words:** Antibiotic resistance, Antimicrobial resistance, AMR related mortality, length of hospital
39 stays (LOS) and Disability Adjusted Life Years (DALYs)

40

41 **Background**

42 The Murry et al 2019 review of the global AMR burden showed a grim picture of accelerated
43 progression towards the 2015 predictions on the impact of antimicrobial resistance (AMR) on global
44 health and economic growth (1). Eight years after the prediction that AMR would kill 10 million people
45 annually by 2050, up to 1.27 million deaths in 2019 were attributed to AMR, surpassing the previous
46 leading infectious killers including tuberculosis, malaria and Human Immuno-deficiency Virus (HIV)
47 (1). Over one million of these deaths occurred in the World Health Organization (WHO) African region,
48 of which majority were in Western Sub-Saharan Africa (2). Worryingly, this burden that
49 disproportionately fell on the Africa region, coincided with poor AMR surveillance systems in the
50 region, where the AMR preparedness score was 53% less than the overall Sub-Saharan Africa 2018-
51 2020 Joint External Evaluation (JEE) score, with many countries lacking National Action Plans (NAP)

52 to address the AMR scourge (3). Antimicrobial resistance has dire consequences including the use of
53 more expensive medicines to treat infections and increased length of hospital stay, which lead to higher
54 healthcare costs and reduced economic productivity [9]. Moreover, resistant infections make
55 undertaking of medical procedures like organ transplants, surgeries and chemotherapy risky (4). To
56 reverse this AMR ascendance and its impact, interventions will need to be based on a wider evidence
57 base of the AMR burden including the clinical outcomes, AMR related economic burden, and disability,
58 which is scarce in the WHO Africa region (1).

59 Despite the growing global attention on AMR, there are substantial limitations in our understanding of
60 the burden, its distribution and the determinants at the population level (5). Currently, majority of the
61 available AMR data describe resistance profiles or mechanism of resistance (6). While this data is
62 important for surveillance and design of treatment protocols, data on AMR burden including clinical
63 outcomes like mortality, disability, length of stay, and their determinant is critical in informing
64 planning, resource mobilization and allocation, policy formulation, and the design of targeted control
65 strategies.

66 Individuals who survive AMR have increased Disability Adjusted Life Years (DALYs) including the
67 years of life lost (YLL) and year lived with disability (YLD). DALYs measure the burden of disease:
68 reduction in life expectancy and diminished quality of life due to the disease (7). Consequently, studying
69 the distribution of DALYs in the community helps to know which communities bear the greatest burden
70 of the disease and to focus interventions on these areas [10]. Cassini et al found that DALYs due to
71 AMR (170 per 100 000) were similar to DALYs due to influenza, tuberculosis, and HIV combined (183
72 per 100,000) and 25% (127 of 501 DALYs per 100 000) of the burden of health-care-associated
73 infections (HAIs) was due to AMR (8). Up to 67.9% (115 of 170) of the total DALYs were accounted
74 for by four antibiotic-resistant bacteria: third-generation cephalosporin-resistant *Escherichia coli*,
75 Methicillin resistant *Staphylococcus aureus* (MRSA), carbapenem-resistant *Pseudomonas aeruginosa*,
76 and third-generation cephalosporin-resistant *Klebsiella pneumoniae* (8). The data indicates a high
77 disease burden posed by AMR.

78 Determination of the AMR related mortality, length of hospital stay, DALYs and the influencing factors
79 would complement the routine surveillance data that has been accrued during the implementation of the
80 2018 – 2023 NAP (9-11), and offer a comprehensive description of the AMR burden in Uganda. This
81 study therefore provides a more comprehensive description of the Uganda AMR burden in terms of
82 attributable mortality, DALYs and the driving factors. This information is critical in the campaign to
83 have the Uganda government adopt AMR surveillance in its health prioritization, planning, resource
84 mobilization and allocation.

85

86 **Methodology**

87 This was a retrospective study of the AMR related clinical outcomes, length of hospital stay, and
88 associated factors using clinical records of patients with infectious syndromes admitted at Arua, Jinja
89 and Mbale regional referral hospitals (RRH) between October 2022 and September 2023. The records
90 were accessed between 4th and 23rd October 2023. The researchers had access to personal identification
91 information during the data collection but not afterwards. Arua RRH is located in Northwest-Nile
92 region, about 500 km from Uganda's capital, Kampala while Jinja and Mbale RRHs are located about
93 100 km and 400 km respectively from Kampala in the Eastern part of Uganda. Arua, Jinja, and Mbale
94 RRHs serve catchment populations of 3.5, 4.5, and 4.6 million people respectively (12-14).

95 A data abstraction form was designed, pretested and digitalized using Kobo Toolbox, a free and open-
96 source suite of tools for field data collection. Digitalization included building checks in the abstraction
97 tool to ensure quality of the data collected. A team of clinicians were recruited and trained on the
98 protocol, data abstraction tool, and data collection standard operating procedures before data collection.

99 There was a two-tier review of the data by supervisors and a data manager to ensure completeness of
100 the data collected. Abstraction targeted clinical records of patients with infectious syndromes seen at
101 the participating hospital in the 12 months prior to the study who had culture and sensitivity testing
102 done. The study variables abstracted included referral status, prior antibiotic use, admission date,
103 admission diagnosis, sampling date, comorbidities, antimicrobial susceptibility testing (AST) results,

104 antibiotics prescribed after culture, treatment outcome, length of hospital stay, and discharge date or
105 date of death, among others.

106 **Sample size consideration**

107 Sample size was determined using the University of San Francisco online sample size calculator (15),
108 based on a pooled prevalence of MRSA of 49% and 35% among HIV infected and HIV uninfected
109 respectively (7) and calculated odd ratios (OD) and relative risk (RR) of 1.78 and 1.4 respectively (16).
110 A sample size of 388 records was sufficient to determine the study variables at 80% power and 95%
111 confidence interval (CI).

112 **Statistical analysis**

113 Statistical analysis was conducted in Stata 18. Continuous variables were reported as median and
114 interquartile range (IQR) and categorical variables as proportions in terms of frequencies and
115 percentages. The association between having or not having an Antibiotic Resistant Infections (ARI) and
116 other categorical variables was determined using the Chi-square test of independence while for
117 continuous variables, we utilized the Two-sample Wilcoxon rank-sum (also known as the Mann-
118 Whitney) test. The resulting p-values provided the level of statistical significance for each variable
119 examined. A modified Poisson regression model was fitted on complete cases (N=224) to determine
120 factors associated with ARI, and Prevalence Ratios at 95% CI were obtained. Factors with p-value <
121 0.2 in the un-adjusted model were selected into the adjusted model. The DALYs were calculated as a
122 sum of YLL and YLD. YLL was determined as number of deaths multiplied by the standard life
123 expectancy at age of death. Since we dealt with individual data, YLL was taken as the average standard
124 life expectancy at age of death. YLD was determined as the number of new cases of a disease multiplied
125 by Disability Weight (DW) multiplied by the average time a person lives with a disease before
126 remission. The length of hospital stay was obtained as the difference between the date of discharge or
127 date of death and date of admission. At all levels of comparisons, a p-value of < 0.05 was taken as
128 statistically significant.

129

130 **Ethical statement**

131 The study was approved by the Makerere University School of Biomedical Sciences Institutional
 132 Review Boards (SBS-2023-329), which granted a waiver of consent to use the clinical records of
 133 patients with infectious syndromes at the participating hospitals. The study was also approved by the
 134 Uganda National Council of Science and Technology (HS3088ES).

135 **RESULTS**

136 Data was abstracted from 392 records but 101 records for tuberculosis patients were excluded from this
 137 analysis because they heavily skewed the data because of the characteristic long length of stay in
 138 hospital. In *table 1*, socio-demographic characteristics of 291 participants were examined. Among them,
 139 52.6% were males, 10% were living with HIV, and the median age was 35 years (IQR: 21-56 years).

140 **Table 1: Distributions of demographic characteristics and other factors by antibiotic resistant**
 141 **infections**

Characteristic	Total N(Col%)	Antibiotic Resistant Infection (ARI)		P-value
		No n(Row%)	Yes n(Row%)	
Overall	291	205(70.4%)	86 (29.6%)	
Name of Facility				
Arua Regional Referral Hospital	149(51.2)	127(85.2)	22(14.8)	<0.001^c
Jinja Regional Referral Hospital	60(20.6)	41(68.3)	19(31.7)	
Mbale Regional Referral Hospital	82(28.2)	37(45.1)	45(54.9)	
Sex				0.018^c
Female	138(47.4)	88(63.8)	50(36.2)	
Male	153(52.6)	117(76.5)	36(23.5)	
Age in years (Median (IQR))	35(21-56)	35(24-56)	35(20-56)	0.852 ^m
Length of Hospital stay in days (Median (IQR)) (N=230)	14(6.0-31.0)	12(6.0-25.5)	25.5(10.0-43.0)	0.001^m
Underlying Chronic co-morbid conditions				0.152 ^c
No	199(68.38)	135(67.8)	64(32.2)	
Yes	92(31.62)	70(76.1)	22(23.9)	
Patient referral				0.644 ^c
No	246(84.5)	172(69.9)	74(30.1)	
Yes	45(15.5)	33(73.3)	12(26.7)	
Referral Category (N=44)				0.579 ^f
Lower-level public health facility	32(72.73)	23(71.88)	9(28.12)	
Private health facility	12(27.27)	9(75.00)	3(25.00)	
Died (Treatment Outcome)				0.030^c
No	161(55.33)	105(65.2)	56(34.8)	
Yes	130(44.67)	100(76.9)	30(23.1)	
MDRI				<0.001^c
No	239(82.1)	205(85.8)	34(14.2)	
Yes	52(17.9)	0(0.0)	52(100.0)	
Prior antibiotic use				0.244 ^f
No	4(1.37)	4(100.0)	0(0.0)	

Yes	287(98.63)	201(70.0)	86(30.0)	
HIV Status				0.501 ^c
No	262(90.0)	183(69.9)	79(30.2)	
Yes	29(10.0)	22(75.9)	7(24.1)	
Clinical Diagnosis at Admission				0.004 ^f
Diarrhea	1(0.3)	1(100.0)	0(0.0)	
Enteric fever	2(0.7)	0(0.0)	2(100.0)	
Meningitis	8(2.8)	8(100.0)	0(0.0)	
Pneumonia	28(9.6)	26(92.9)	2(7.1)	
Sepsis	127(43.6)	84(66.1)	43(33.9)	
UTI	10(3.4)	8(80.0)	2(20.0)	
Other infections	11(39.5)	78(67.8)	37(32.2)	

142 Col % stands for column percentage, Row % stands for row percentages, IQR stands for inter quantile range, n
 143 stands for absolute frequencies, m stands for Mann-Whitney U test, c stands for Pearson Chi-square, and f stands for
 144 Fisher's Exact test.

145 *Prevalence of ARI and mortality*

146 The prevalence ARI was 29.6%, while that for multi-drug resistant infections (MDRI) was 17.9%.
 147 Overall, mortality due to an infectious syndrome was 44.7%, of which 34.9% was due to ARI while
 148 30.8% of the mortality due to ARI, the causative pathogens were multidrug resistant (MDR), *table 2*.
 149 The 30-day mortality was 23% compared to 30% for length of stay longer than 30 days, *table 3*.
 150 Additionally, 31.6% of participants had underlying comorbid conditions, with HIV (32%) and diabetes
 151 (29%) being the most common. Participants with comorbidities had a high mortality (45%) compared
 152 to those without comorbidities (31%), *table 4*. Sepsis (43.6%) and diarrhea (9.6%) were the most
 153 common infectious syndromes, *table 5*.

154 **Table 2: Mortality due to Antibiotic Resistant Infection**

Characteristic (N=86)	Frequency (Col %)
Multi-Drug Resistant Infections (MDRI)	
No	239 (82.10)
Yes	52 (17.90)
Died with ARI (n=86)	
No	56 (65.10)
Yes	30 (34.90)
Died with MDRI (n=52)	
No	36 (69.20)
Yes	16 (30.80)

155

156 **Table 3: 30-day mortality due ARI**

<30 day mortality	
Number of people who died due to ARI with <30 day LOS and ARI	13
Total number of people that died wit ARI	56

% Mortality	23%
>30 day mortality	
Number of people who died due to ARI with >30 day LOS and ARI	17
Total number of people that died wit ARI	56
% Mortality	30%

157

158 **Table 4: Mortality among those with comorbidities.**

Mortality of patients with comorbidities that also had ARI	Frequency (Col %)
Number of patients who had ARI, comorbidities and also died	10
Number of patients that had ARI and comorbidities	22
Mortality due to ARI for patients with comorbidities	45%
Mortality of patients with ARI but had no comorbidities	
Number of patients who had ARI, and died but had no comorbidities	20
Number of patients that had ARI and no comorbidities	64
Mortality due to ARI for patients with comorbidities	31%

159

160 **Table 5: Clinical Syndromes contributing to death**

Clinical Syndrome	Number of Deaths	Percentage
Sepsis	55	42.3
Other infections	43	33.1
Pneumonia	20	15.4
Meningitis	8	6.2
Enteric fever	2	1.5
UTI	2	1.5

161

162 *Causes of mortality*

163 Most deaths were due to sepsis (42.3%) followed by pneumonia (15.4%) and meningitis (6.2%). Among
 164 the Gram-negative bacteria, *Escherichia coli* (7.8%) followed by *Klebsiella* spp (5.5%) contributed
 165 most to mortality while among the Gram-positives, *Staphylococcus aureus* and *Enterobacter* spp
 166 contributed equally (2.3%) to mortality. Notably, 85.7% of the deaths were due to ESKAPE organisms
 167 (*Staphylococcus aureus*, *Klebsiella* spp, *Pseudomonas aeruginosa*, and *Enterobacter* spp), table 6.

168 **Table 6: Organisms Contributing to Mortality**

Organism isolated	Frequency	Percentage
<i>Citrobacter</i> spp	2	1.56
<i>Escherichia coli</i>	10	7.81
<i>Enterobacter</i> spp	3	2.34
<i>Klebsiella</i> spp	7	5.47

<i>Proteus spp</i>	1	0.78
<i>Pseudomonas spp</i>	1	0.78
<i>Serratia Mascensens</i>	1	0.78
<i>Staphylococcus aureus</i>	3	2.34
No significant growth	100	78.13

169

170 *Factors associated with ARI*

171 Patients at Jinja RRH exhibited a 2.42 times higher likelihood of ARI compared to those at Arua RRH
 172 (95% CI: 1.43-4.12, p=0.001). Similarly, patients at Mbale RRH had a 2.67 times higher likelihood of
 173 ARI compared to those at Arua RRH (95% CI: 1.53-4.58, p < 0.001). A log unit increase in length of
 174 hospital stay in days was associated with 21% higher risk of ARI (95% CI: (1.15-1.95), p=0.003) while
 175 mortality was 1.4 (95% CI: 1.00-1.97) times higher among the ARI but this was not statistically
 176 significant, *table 7*. For consideration of length of stay and risk of death, ARI related death ratio was
 177 0.76(95% CI: 0.69-0.85), p<0.001 for the log-transformed length of hospital stay, which indicated that
 178 for every one-unit log increase in the length of hospital stay, the death rate decreased by approximately
 179 24% (p<0.001, 95% CI: (0.69-0.85)) for patients, *table 7*.

180 **Table 7: Factors associated with having an antibiotic resistant infection**

Characteristic	Un-adjusted PR (95% CI)	P-Value	Adjusted PR (95% CI)	P-value
Name of facility				
Arua Regional Referral Hospital	Reference		Reference	
Jinja Regional Referral Hospital	2.14(1.25-3.67)	0.005	2.42(1.43-4.12)	0.001
Mbale Regional Referral Hospital	3.72(2.41-5.73)	<0.001	2.65(1.53-4.58)	<0.001
Sex				
Female	1.54(1.07-2.21)	0.019	1.49(0.96-2.32)	0.075
Male	Reference		Reference	
Length of hospital stay (per unit log increase)	1.36(1.19-1.55)	<0.001	1.50(1.15-1.95)	0.003
Age (Years)	1.00(0.99-1.01)	0.852	N/A	N/A
Underlying chronic comorbid condition				
No	Reference		Reference	
Yes	0.74(0.49-1.12)	0.164	0.71(0.44-1.13)	0.148
Patient referral				
No	Reference		N/A	N/A
Yes	0.89(0.53-1.49)	0.651	N/A	N/A
Died (Treatment outcome)				
No	Reference		Reference	
Yes	0.66(0.45-0.97)	0.034	1.31(0.88-1.96)	0.189
HIV status				
Negative	Reference		N/A	N/A
Positive	0.80(0.41-1.57)	0.517	N/A	N/A

181 PR denotes Prevalence Ratios and 95% CI denotes the 95% Confidence interval obtained by fitting a modified Poisson
 182 regression model on complete cases (N=224). Factors were selected into the adjusted model if p-value<0.2 at un-adjusted.

183 *Disability adjusted life years (DALYs)*

184 The DALYs for participants with ARI were 235.4, higher than the DALYs for participants without ARI,
185 147.0.

186

187

188 **Discussion**

189 We provide the first description of bacterial AMR burden including mortality and DALYs in Uganda,
190 a low-income country. Our evaluation reveals a high mortality: 34.9% due to ARI, of which 30.8% was
191 due to MDRI. Moreover, this mortality occurred in presence of a high rate of comorbidities including
192 HIV (32%) and diabetes (29%) and these patients with comorbidities had a higher mortality (45%)
193 compared to those without (31%). Hospital length of stay was 1.2 times higher for patients with ARI
194 compared to those without. A unit increase in length of hospital stay was associated with a 24%
195 reduction in mortality, indicating early mortality before or shortly after AMR has been diagnosed. Most
196 death were due to sepsis, mainly as a result of Gram-negative bacteria, *Escherichia coli* and *Klebsiella*
197 *spp* in particular as well as *Staphylococcus aureus* and *Enterococcus spp* among the Gram-positives,
198 with the ESKAPE group accounting for 85.7% of the deaths. All these contributed to higher YLD and
199 DALYs associated with ARI: 189 and 235.4 compared to 101.7 and 147.0 for non-ARI respectively.

200 We noted a high AMR related mortality, with a significant proportion being due to MDRI, which is
201 similar to what has been observed elsewhere. Globally, AMR is surpassing previously leading
202 infectious causes of death: 1.27 million deaths and 4.95 million deaths were related or associated to
203 AMR in 2019, higher than that due to malaria, tuberculosis or HIV/AIDS (1). In the same year, in the
204 WHO African region, 1.05 million deaths and 250,000 deaths were due to and attributed to AMR
205 respectively, the highest mortality rate (23.5 per 100,000) globally (2). Resistant *Escherichia coli*,
206 among the leading six pathogens causing mortality in the same evaluation, has been associated with an
207 absolute risk of mortality of 58 – 130 per 1000 regardless of the type of resistance (17). South Asia
208 shares with Sub-Saharan Africa the brunt of the AMR burden. Overall, case fatality among neonates

209 admitted to the Neonatal Intensive Care Unit (NICU) in Vietnam was 44.4% with a 31.8% 30-day
210 mortality rate, a 27% increase in odds of fetal outcome and a 2.1 day increase in hospital length of stay
211 (18). A systematic review by Kassim et al reported that AMR increased the mortality due to bloodstream
212 infection by 58% and doubled the risk of ICU admissions (19). The risk of death due to AMR affects
213 both community acquired and hospital acquired (CAI, HAI), where the resistant infections in either type
214 have a higher risk of death (20, 21). AMR has been hitherto an unrecognized infectious cause of death
215 in Uganda. In 2019, up to 7100 deaths were due to AMR while another 30700 deaths were associated
216 with AMR, leaving Uganda with the 165th highest age standardized AMR related mortality among 204
217 countries (22). Moreover, the AMR related mortality was higher than the previously leading causes of
218 death including tuberculosis, HIV/AIDS and Malaria (22). In this study, the Gram-negative bacteria
219 (*Escherichia coli* and *Klebsiella* spp) were responsible for most of the deaths while *Staphylococcus*
220 *aureus* and *Enterococcus* spp contributed most among the Gram-positive. These were among the six
221 leading causes of death in 2019 while others included *Streptococcus pneumoniae*, *Acinetobacter*
222 *baumannii*, and *Pseudomonas aeruginosa* (1). In the African region, *Streptococcus pneumoniae*,
223 *Klebsiella pneumoniae*, *Escherichia coli*, and *Staphylococcus aureus*, were the four leading causes of
224 death while third-generation cephalosporin-resistant *Klebsiella pneumoniae* and methicillin-resistant
225 *Staphylococcus aureus* (MRSA) were the leading pathogen–drug combinations associated with
226 mortality (2). These findings highlight an urgent need to address the AMR challenge, targeting the
227 pathogens responsible for the highest burden in Uganda and the African region at large.

228 Diabetes and HIV/AIDS were highly prevalent among AMR patients, and although presence of
229 comorbidities was not independently associated with AMR, it carried a heightened risk of death.
230 Hyperglycemia impairs the immunity (23), increasing the risk for infectious syndromes like skin and
231 soft tissue infections, urinary tract infections, surgical site infection, and respiratory tract infections
232 among others (24). Relatedly, drug resistant infections are also increased, for instance multidrug-
233 resistant *Klebsiella pneumoniae* and MRSA were more common in hyperglycemic patients compared
234 to normoglycemic patients (25). There has been contrasting evidence on the risk of AMR posed by
235 diabetes: higher AMR was observed in diabetic patients with liver abscess (26) while carbapenem-

236 resistant *Klebsiella pneumoniae* was lower among diabetics compared non-diabetics (27). High
237 resistance has been noted in common bacteria isolated from diabetic foot: *Staphylococcus aureus*
238 against gentamicin (57.96%), and ciprofloxacin (52.45%) and *Escherichia coli* and *Klebsiella*
239 *Pneumoniae* resistance against common antibiotics at more than 50% (28). Overall, AMR is likely to
240 have a higher impact in diabetics due to their heightened risk of infection and frequent exposure to
241 healthcare environment (29). HIV/AIDS was also highly prevalent among patients with AMR in our
242 study. HIV/AIDS weakens the immune system, making individuals prone to infections in addition to
243 the frequent visits to healthcare facilities, which exposes them to infections. HIV/AIDS is associated
244 with high rates of AMR (30): a systematic review showed that people living with HIV (PLWH) were
245 twice as likely to be colonized (31) or infected with MRSA, *Streptococcus pneumoniae* resistant to
246 penicillin, and third-generation cephalosporins resistant *Escherichia coli* and *Klebsiella pneumoniae*
247 (32). Infection prevention measures targeting individuals and hospital or home environment (33), and
248 stewardship practices in the use of antibiotics, in addition to optimized HIV/AIDS care to ensure
249 recovery and sustenance of a robust immune system, are critical measures to protect PLWH from AMR.

250 On the other hand, we had only few cancer patients in the study as the study was done in a general ward
251 setting. Cancer is a recognized immune suppressive condition including the immune suppressive effect
252 of its treatment while surgery or bone marrow related cancer treatments rely on effective infection
253 prevention or treatment (34). Fifty percent (50%) of cancer deaths are due to infections but deaths due
254 to AMR have not been well described (35). However, high rates of AMR especially in ESKAPE
255 organisms, have been reported in cancer patients: Vancomycin Resistant *Enterococcus* (VRE, 80%),
256 fluoroquinolone resistant *Escherichia coli* (70%), and MRSA (50%), among others (36). Consequences
257 of AMR among cancer patients include increased persistence of bacteremia (25% vs 9.7%), metastatic
258 infection (8% vs 4%), and early case-fatality rates (23% vs 11%) among infections due to resistant
259 ESKAPE pathogens versus other bacteria (36). Moreover, MDR is rampant in cancer patients: 40% in
260 ICU patients including 20% *Escherichia coli* (94.4% ESBL), 12% *Staphylococcus aureus* (90.6%
261 MRSA), 12% *Enterococcus faecium* (18.7% VRE), and 6% *Acinetobacter baumannii* (36). The high

262 burden of comorbidities and associated risk of AMR and the related adverse outcomes highlight the
263 urgent need for strategies to curtail the threat posed by the comorbidities.

264 Our study's finding that patients with AMR stayed 1.2 times longer in hospital than patients without
265 AMR, is similar to finding by a study in Ghana, where AMR patients stayed 5 days and 8 days longer
266 than patients with susceptible infections and non-infected patients respectively (19, 37). This is far
267 more than what was found in France, where the excess length of stay due to AMR was only 1.6 days,
268 and 2.9 days in Australia (38, 39). This highlights the difference between the first world and low
269 resource settings. In the first world appropriate diagnostics can aid in early identification of AMR and
270 alternative options of treatment are more available. Long stay in hospital is associated with higher
271 consumption of hospital resources, higher expenditure for the patient, loss of economic productivity
272 and risk of mortality. For instance, in the Ghana study, AMR related costs were USD 1300 higher than
273 those due to susceptible infections, with 30% of the costs being due to loss of productivity through
274 presenteeism and absenteeism (37). Relatedly, the average AMR related cost was less in France (USD
275 1173) (38) while 40% of AMR related costs in Europe and the United States were also due to loss of
276 productivity (40). A systematic review by Kassim et al estimated a direct cost per AMR case of USD
277 12,000 in low and middle income countries (LMICs) (19). Hospital acquired infections are more
278 commonly MDR, posing an intense challenge to healthcare. Mauldin et al found that hospital costs and
279 length of hospital stay due to resistant Gram-negative HAI were 29.3% and 23.8% higher than those
280 due to susceptible Gram-negative bacteria (41). On the contrary, however, Wonziak et al did not find
281 any significant difference in length of hospital stay between drug resistant and drug susceptible CAI in
282 Australia (20), as did Barassa et al (42) in Spain. Suzuki et al also found negligible additional length of
283 stay (0.8 days) attributable to resistant *Escherichia coli* and *Klebsiella* spp compared to the prolonged
284 length of stay already imposed by bacteremia due to the same organisms (43). In our study every unit
285 increase in time in hospital was associated with a 24% reduction in mortality. Much as the effect of
286 AMR on length of hospital stay has been widely studied, its effect on or relation with mortality has not
287 been fully evaluated. The finding of reduced mortality with a unit increase in length of stay may imply

288 early mortality due AMR before appropriate diagnosis is made or before appropriate treatment is
289 instituted, implying that those who survive through the early events have higher chances of survival.

290 By accounting for healthy life years lost due to premature death and years lost living with disabilities,
291 DALYs offer a better estimate of burden of disease (44). We found that the DALYs due ARI (235)
292 were almost two times higher than those due to non-ARI (147). AMR related DALYs in our setting
293 were close but higher than DALYs observed in Japan (195) in 2021 (45) but two and four times higher
294 than those in Switzerland (98) and German (57) respectively in 2023 (46), highlighting that low resource
295 settings bear a significantly higher AMR burden. Moreover, the magnitude of DALYs can be affected
296 by type of pathogen (*Staphylococcus aureus*, *Acinetobacter baumannii*, and *Streptococcus pneumoniae*
297 are associated with higher DALYS), sex (higher in male except in women in the reproductive age
298 groups), and site of infection (blood stream infections and bone and joint infection are associated with
299 higher DALYs) while geographical and socio-demographic differences have also been noted (45, 47,
300 48). These differences likely result from the effect of these parameters on the components used to
301 calculate YLL and YLD particularly number of deaths, incidence of AMR cases, and disability weights.
302 Availability of diagnostic tests and alternative options of treatment for AMR which affect risk of death
303 or the time one stays with the resistant infection, might also explain the difference between high versus
304 low income settings.

305 We note that the admitting hospital and length of stay in hospital were independently associated with
306 ARI. The three admitting hospitals are located within cities, however, the communities in eastern part
307 of the country are more urbanized than those in the north. Bacterial activity, antibiotic resistant genes,
308 and MDR bacteria in the environment have been noted to increase with urbanization and to differ by
309 level of urbanization, with population size as a key driving factor (49). Conditions in urban centers
310 including; poor housing, poor drainage and poor sanitation; poorly-regulated and private provision of
311 medical services including access to antimicrobials, poor waste management, and increased demand for
312 food-animals associated with inappropriate use of antibiotics as growth-promoters, which drive
313 emergence and transmission drug resistant infection, increase with urbanization (5). Mauldin et al also
314 showed that parameters associated with increased hospital costs and length of stay respectively

315 included pneumonia diagnosis (43.8% vs. 38.2%), ICU admission (142% vs. 106%), neutropenia
316 (83.5% vs. 70.9%) and organ transplant (115.8% vs. 74%) while patients 12 years or more had a 26.3%
317 lower hospital cost but a 66.8% lower length of stay versus those younger (41). Among patients referred
318 for long term care in Chicago, USA, presence of a feeding tube and polymicrobial infection were
319 associated with ARI while urinary catheter, decubitus ulcer, prior use of antibiotics and previous
320 admission within 30 days of current admission were not (50). On the other hand, MDR *Pseudomonas*
321 *aeruginosa* infection was independently association with sex, age, and comorbidities, and correlated
322 with ventilation history and neutropenia (51). On the other hand, cotrimoxazole, amikacin, or imipenem
323 except cefazolin; admission to ICU and prior use of acid-suppressive medication were associated with
324 infection with MDR organisms (52). These factors can be targeted by strategies to control AMR and
325 those to improve patient outcomes.

326 Our study strength lies in it being the first expanded description of AMR burden in Uganda, a resource
327 limited setting, revealing critical data that can inform strategies to control AMR, improve clinical
328 outcomes as well as planning and resource allocation. It was limited in geographical scope as only two
329 regions of Uganda were represented, which may not be representative of other regions in the country.
330 Finally, because of the retrospective design, there was missing data on some of the critical parameters
331 that would have been of interest to evaluate.

332 **Conclusion/recommendation**

333 Uganda faces a high AMR burden characterized by a high mortality and a high rate of MDR infections,
334 high DALYs and increased length of hospital stay, in a setting of a high rate of comorbidities including
335 HIV and diabetes. Sepsis, majorly due to resistant Gram-negative bacteria, contributed most to the
336 AMR burden. While these findings can shape the early targeted AMR control strategies, a larger
337 evaluation covering all regions of the country to comprehensively describe the burden is urgently
338 needed.

339 **Author contribution**

340 Jonathan Mayito, Conceptualization, Investigation, Methodology, Project Administration, Writing –
341 Original Draft Preparation

342 Flavia Dhikusooka, statistical analysis, Review and Editing

343 Daniel Kibombo, Investigation, Methodology, Writing – Review & Editing

344 Alex Andema, Writing – Review & Editing

345 Stephen Obbo, Writing – Review & Editing

346 Alfred Yayi, Writing – Review & Editing

347 Richard Walwema, Resource, Methodology, Supervision, Writing – Review & Editing

348 Francis Kakooza, Resources, Methodology, Supervision, Writing – Review & Editing

349 **Conflict of interest**

350 All authors report no conflict of interest

351 **Financial disclosure**

352 This work was funded by the Royal Society of Tropical Medicine and Hygiene (RSTMH) Early Career

353 Award in partnership with the National Institute for Health and Care Research (NIHR).

354 **References**

355 1. Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in
356 2019: a systematic analysis. *Lancet*. 2022 Feb;399(10325):629-55.

357 2. Antimicrobial Resistance Collaborators. The burden of bacterial antimicrobial resistance in the
358 WHO African region in 2019: a cross-country systematic analysis. *Lancet*. 2023 Dec;12(2):E201-E16.

359 3. Elton L, Thomason MJ, tembo J, et al. Antimicrobial resistance preparedness in sub-Saharan
360 African countries. *BMC*. 2020;145(9).

361 4. WHO. Antimicrobial resistance. [Internet]. 2021 Nov.

362 5. Allcock S, Young EH, Holmes M, Gurdasani D, Dougan G, Sandhu MS, et al. Antimicrobial
363 resistance in human populations: challenges and opportunities. *Glob Health Epidemiol Genom*. 2017
364 May 10;2:e4.

365 6. Kivumbi MT, Standley CJ. Efforts to Identify and Combat Antimicrobial Resistance in Uganda:
366 A Systematic Review. *Trop Med Infect Dis*. 2021 May;6(2):86.

367 7. Global Health CEA. The DALYs. [Internet].

368 8. Cassini A, Högberg LD, Plachouras D. Attributable deaths and disability-adjusted life-years
369 caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in
370 2015: a population-level modelling analysis. *Lancet Infect Dis*. 2019 Jan;19(1):56–66.

- 371 9. Nabadda S, Kakooza F, Kiggundu R, et al. Implementation of the World Health Organization
372 Global Antimicrobial Resistance Surveillance System in Uganda, 2015-2020: Mixed-Methods Study
373 Using National Surveillance Data. *JMIR Public Health Surveill.* 2021 Oct 7(10)::e29954.
- 374 10. Mugerwa I, Nabadda SN, Midega J, et al. Antimicrobial Resistance Situational Analysis 2019-
375 2020: Design and Performance for Human Health Surveillance in Uganda. *Trop Med Infect Dis.* 2021
376 Sep;6(4):178.
- 377 11. Mayito J, Kibombo D, Olaro, et al. Characterization of Antibiotic Resistance in Select Tertiary
378 Hospitals in Uganda: An Evaluation of 2020 to 2023 Routine Surveillance Data. *Trop Med Infect Dis*
379 2024;9(4):77.
- 380 12. Mbale RRH. Mbale Regional Referral Hospital. [Hospital website].
- 381 13. Peaditric Health Initiative. Jinja Regional Referral Hospital. [Internet].
- 382 14. Ministry of Health. Arua Regional Referral Hospital. [Internet].
- 383 15. Francisco UoCS. Sample Size Calculators for designing clinical research. [Internet].
- 384 16. Olaru I D, Acconelli E, Yeung E, et al. The association between antimicrobial resistance and HIV
385 infection: a systematic review and meta-analysis. *CMI.* 2021 Jun;27(6):P846-53.
- 386 17. MacKinnon MC, Sargeant JM, Pearl DL, et al. Evaluation of the health and healthcare system
387 burden due to antimicrobial-resistant *Escherichia coli* infections in humans: a systematic review and
388 meta-analysis. *Antimicrob Resist Infect Control* 2020;9(200).
- 389 18. Peters L, Olson L, Khu DTK, Linnros S, Le NK, Hanberger H, et al. Multiple antibiotic resistance
390 as a risk factor for mortality and prolonged hospital stay: A cohort study among neonatal intensive
391 care patients with hospital-acquired infections caused by gram-negative bacteria in Vietnam. *PLoS*
392 *ONE* 2019;14(5):e0215666.
- 393 19. de Kraker MEA. Understanding the impact of antimicrobial resistance on outcomes of
394 bloodstream infections in low- and middle-income countries. *PLoS Med.* 2023;20(7):e1004262.
- 395 20. Wozniak TM, Dyda A, Lee X. The Increased Length of Hospital Stay and Mortality Associated
396 With Community-Associated Infections in Australia. *Open Forum Infect Dis.* 2022 Mar;9(5):ofac133.
- 397 21. Neubeiser A, Bonsignore M, Tafelski CS, Alefelder C. Mortality attributable to hospital
398 acquired infections with multidrug-resistant bacteria in a large group of German hospitals. *Journal of*
399 *Infection and Public Health.* 2020 Feb;13(2):204-10.
- 400 22. IHME. The burden of antimicrobial resistance (AMR) in Uganda. [Internet]. 2019.
- 401 23. Shah BR, Hux JE. Quantifying the risk of infectious diseases for people with diabetes. *Diabetes*
402 *Care.* 2003;26:510-3.
- 403 24. Akash MSH, Rehman K, Fiayyaz F, Sabir S, Khurshid M. Diabetes-associated infections:
404 development of antimicrobial resistance and possible treatment strategies. *Arch Microbiol.* 2020
405 Jul;202(5):953-65.
- 406 25. Yi H, Huang J, Guo L, Zhang Q, Qu J, M Z. Increased Antimicrobial Resistance among Sputum
407 Pathogens from Patients with Hyperglycemia. *Infection and drug resistance.* 2020;13.
- 408 26. Tian LT, Yao K, Zhang XY, al. e. Liver abscesses in adult patients with and without diabetes
409 mellitus: an analysis of the clinical characteristics, features of the causative pathogens, outcomes and
410 predictors of fatality: a report based on a large population, retrospective study in China. *Clin Microbiol*
411 *Infect.* 2012;18(E314-30).
- 412 27. Tian L, Tan R, Chen Y, al e. Epidemiology of *Klebsiella pneumoniae* bloodstream infections in
413 a teaching hospital: factors related to the carbapenem resistance and patient mortality. *Antimicrob*
414 *Resist Infect Control.* 2016;5:48.
- 415 28. Wada FW, Mekonnen MF, Sawiso ED, et al. Bacterial profile and antimicrobial resistance
416 patterns of infected diabetic foot ulcers in sub-Saharan Africa: a systematic review and meta-analysis.
417 *Sci Rep.* 2023;13:14655.
- 418 29. Dunachie S, Chamnan P. The double burden of diabetes and global infection in low and
419 middle-income countries. *Transactions of The Royal Society of Tropical Medicine and Hygiene.* 2019
420 Feb;113(2):56-64.

- 421 30. Jemal M, Deress T, Belachew T, Adem Y. Antimicrobial Resistance Patterns of Bacterial Isolates
422 from Blood Culture among HIV/AIDS Patients at Felege Hiwot Referral Hospital, Northwest Ethiopia.
423 *Int J Microbiol.* 2020 Oct;8893266.
- 424 31. Henderson HI, Ruegsegger L, Alby K, et al. Antimicrobial-resistant Enterobacterales
425 colonization in people with HIV. *JAC-Antimicrobial Resistance.* 2022 Aug;4(4):dlac082.
- 426 32. Olaru ID, Tacconelli E, Yeung S, Ferrand RA, Stabler RA, Hopkins H, et al. The association
427 between antimicrobial resistance and HIV infection: a systematic review and meta-analysis. *Clin*
428 *Microbiol Infect.* 2021 Jun;27(6):846-53.
- 429 33. Livesley N. PROTECTING PATIENTS WITH HIV FROM ANTIMICROBIAL RESISTANT ORGANISMS.
430 *AMR Control.* 2016 Jul.
- 431 34. Bratti VF, Wilson BE, Fazelzad R, et al. Scoping review protocol on the impact of antimicrobial
432 resistance on cancer management and outcomes. *BMJ Open.* 2023 Feb;13(2):e068122.
- 433 35. Zembower TR. Epidemiology of infections in cancer patients. *Cancer Treat Res.* 2014;161:43-
434 89.
- 435 36. AK N, HW B, VG F, et al. Antibiotic resistance in the patient with cancer: Escalating challenges
436 and paths forward. *CA.* 2021 Dec 71(6):488-504.
- 437 37. Otioku E, Fenny AP, Labi A, et al. Attributable Patient Cost of Antimicrobial Resistance: A
438 Prospective Parallel Cohort Study in Two Public Teaching Hospitals in Ghana. *PharmacoEconomics*
439 *Open.* 2023;7:257–71.
- 440 38. Touat M, Opatowski M, Brun-Buisson C, et al. A Payer Perspective of the Hospital Inpatient
441 Additional Care Costs of Antimicrobial Resistance in France: A Matched Case-Control Study. *Appl*
442 *Health Econ Health Policy.* 2019 Jun;17(3):381-9.
- 443 39. Lee XJ, Stewardson AJ, Worth LJ, Graves N, Wozniak TM. Attributable Length of Stay, Mortality
444 Risk, and Costs of Bacterial Health Care-Associated Infections in Australia: A Retrospective Case-cohort
445 Study. *Clin Infect Dis.* 2021 May;72(10):e506-e14.
- 446 40. Prestinaci F, Pezzotti P, Pantosti A. Antimicrobial resistance: a global multifaceted
447 phenomenon. *Pathogens Glob Health.* 2015;109(7):309–18.
- 448 41. Mauldin PD, Salgado CD, Hansen IS, Durup DT, Bosso JA. Attributable hospital cost and length
449 of stay associated with health care-associated infections caused by antibiotic-resistant gram-negative
450 bacteria. *Antimicrob Agents Chemother.* 2010 Jan;54(1):109-15.
- 451 42. Barrasa-Villar JI, Aibar-Remón C, Prieto-Andrés P, et al. Impact on Morbidity, Mortality, and
452 Length of Stay of Hospital-Acquired Infections by Resistant Microorganisms. *Clinical Infectious*
453 *Diseases.* 2017 Aug;65(4):644–52.
- 454 43. Suzuki H, Perencevich EN, Nair R, Livorsi DJ, Goto M. Excess Length of Acute Inpatient Stay
455 Attributable to Acquisition of Hospital-Onset Gram-Negative Bloodstream Infection with and without
456 Antibiotic Resistance: A Multistate Model Analysis. *Antibiotics.* 2020;9(2):96.
- 457 44. WHO. THE GLOBAL HEALTH OBSERVATORY: Explore a world of health data. [Internet].
- 458 45. Tsuzuki S, Koizumi R, Matsunaga N, et al. Decline in Antimicrobial Consumption and Stagnation
459 in Reducing Disease Burden due to Antimicrobial Resistance in Japan. *Infect Dis Ther* 2023;12:1823–
460 34.
- 461 46. Gasser M, Cassini A, Lo Fo Wong D, Gelormini M, Nahrgang SA, Zingg W, et al. Associated
462 deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in
463 Switzerland, 2010 to 2019. *Euro Surveill.* 2023 May;28(20):2200532.
- 464 47. Lewandrowski KU, da Silva RCL, Elfar JC, et al. Disability-adjusted life years from bone and joint
465 infections associated with antimicrobial resistance: an insight from the 2019 Global Burden of Disease
466 Study *International Orthopaedics (SICOT).* 2024.
- 467 48. Zhang C, Fu X, Liu Y, Zhao H, G W. Burden of infectious diseases and bacterial antimicrobial
468 resistance in China: a systematic analysis for the global burden of disease study 2019. *Lancet Reg*
469 *Health West Pac.* 2023 Nov;43:100972.
- 470 49. Zhu J, Li R, Yan Y, Cui L. Urbanization drives the succession of antibiotic resistome and
471 microbiome in a river watershed. *Chemosphere.* 2022 Aug;301:134707.

472 50. Toubes EK, Singh D, Yin R, et al. Risk Factors for Antibiotic-Resistant Infection and Treatment
473 Outcomes among Hospitalized Patients Transferred from Long-Term Care Facilities: Does
474 Antimicrobial Choice Make a Difference? *Clinical Infectious Diseases*. 2003 Mar;36(6):724–30.

475 51. Shbaita S, Abatli S, Sweileh MW, al. e. Antibiotic resistance profiles and associated factors of
476 Pseudomonas Infections among patients admitted to large tertiary care hospital from a developing
477 country. *Antimicrob Resist Infect Control* 2023;12:149.

478 52. Alsehemi AF, Alharbi EA, Alammash BB, et al. Assessment of risk factors associated with
479 multidrug-resistant organism infections among patients admitted in a tertiary hospital - a
480 retrospective study. *Saudi Pharmaceutical Journal*. 2023 Jun;31(6):1084-93.

481

482

483

484